{"id":558731,"date":"2026-06-10T22:00:00","date_gmt":"2026-06-10T20:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/las-farmacoterapias-como-punto-de-inflexion-cuales-son-los-retos-que-se-avecinan\/"},"modified":"2026-06-17T11:00:42","modified_gmt":"2026-06-17T09:00:42","slug":"las-farmacoterapias-como-punto-de-inflexion-cuales-son-los-retos-que-se-avecinan","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/las-farmacoterapias-como-punto-de-inflexion-cuales-son-los-retos-que-se-avecinan\/","title":{"rendered":"Las farmacoterapias como \u00abpunto de inflexi\u00f3n\u00bb: \u00bfcu\u00e1les son los retos que se avecinan?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Actualmente, en el \u00e1mbito de la indicaci\u00f3n MASH, est\u00e1n autorizadas en la UE y en EE. UU. dos opciones terap\u00e9uticas farmacol\u00f3gicas: el semaglutido (s.c.) y el resmetirom (oral). Se trata de un gran avance, sobre todo teniendo en cuenta que, durante mucho tiempo, no se dispon\u00eda de tratamientos farmacol\u00f3gicos autorizados espec\u00edficamente para la indicaci\u00f3n de las enfermedades hep\u00e1ticas esteat\u00f3sicas. Los estudios ESSENCE y MAESTRO-NASH resultaron decisivos. Adem\u00e1s, actualmente se est\u00e1 llevando a cabo un estudio ESSENCE y MAESTRO-NASH con survodutido, y hay muchos otros ensayos cl\u00ednicos previstos o ya en marcha. En una mesa redonda, expertos internacionales debatieron sobre los principales retos y objetivos de los esfuerzos de investigaci\u00f3n actuales.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Flas-farmacoterapias-como-punto-de-inflexion-cuales-son-los-retos-que-se-avecinan%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Actualmente, en el \u00e1mbito de la indicaci\u00f3n MASH, est\u00e1n autorizadas en la UE y en EE. UU. dos opciones terap\u00e9uticas farmacol\u00f3gicas: el semaglutido (s.c.) y el resmetirom (oral). Se trata&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Flas-farmacoterapias-como-punto-de-inflexion-cuales-son-los-retos-que-se-avecinan%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":558735,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"MASH","footnotes":""},"category":[11552,11483,11352,11475,11358,11288],"tags":[91387,94737,82984,94735,11789,51808,94739,83707,77521,77523,17397,94736],"powerkit_post_featured":[],"class_list":["post-558731","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-el-congreso-informa","category-endocrinologia-y-diabetologia","category-estudios","category-gastroenterologia-y-hepatologia","category-medicina-interna-general","tag-enfermedades-hepaticas-esteatosicas-2","tag-essence","tag-esteatohepatitis","tag-esteatohepatitis-asociada-a-una-disfuncion-metabolica","tag-farmacoterapia-es","tag-fase-iii-es","tag-maestro-nash","tag-mash-es-2","tag-masld-es","tag-resmetirom-es","tag-semaglutida-es","tag-survodutid","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-29 00:53:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/558731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=558731"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/558731\/revisions"}],"predecessor-version":[{"id":558736,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/558731\/revisions\/558736"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/558735"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=558731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=558731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=558731"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=558731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}